BioCryst names Dr. Bill Sheridan CDO and Dr. Ryan Arnold CMO effective Sept 15, 2022

BIOCRYST PHARMACEUTICALS INC

Dr. William Sheridan transitions from CMO to Chief Development Officer, focusing on pipeline advancement.
Dr. Ryan Arnold promoted from SVP Global Medical Affairs (since March 2022) to Chief Medical Officer.
Both join Dr. Helen Thackray (Chief R&D Officer) as physicians on leadership team.
Dr. Sheridan joined BioCryst in 2008; Dr. Arnold has 20+ years industry experience including at Amgen, Genzyme, Biogen.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ryan Arnold

Chief Medical Officer

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2022-09-15
Filed: September 14, 2022, 7:59 PM ET

Also effective September 15, 2022, Dr. Ryan Arnold will serve as the Company’s new Chief Medical Officer.

Role change

William P. Sheridan

Chief Development Officer

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2022-09-15
Successor: Ryan Arnold
Filed: September 14, 2022, 7:59 PM ET

Effective September 15, 2022, William P. Sheridan, MBBS, will serve as Chief Development Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ryan Arnold was appointed as Chief Medical Officer at BIOCRYST PHARMACEUTICALS INC.

Action: will serve
Role: Chief Medical Officer

Exact text from the filing

Also effective September 15, 2022, Dr. Ryan Arnold will serve as the Company’s new Chief Medical Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William P. Sheridan changed role as Chief Development Officer at BIOCRYST PHARMACEUTICALS INC.

Action: will serve
Role: Chief Development Officer

Exact text from the filing

Effective September 15, 2022, William P. Sheridan, MBBS, will serve as Chief Development Officer of the Company.

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-22-006097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.